How Nucala Targets Asthma Inflammation
Nucala (mepolizumab) treats severe eosinophilic asthma by blocking interleukin-5 (IL-5), a protein that stimulates eosinophils—white blood cells that drive airway inflammation in this asthma type. Eosinophils release toxic proteins and chemicals that swell airways, narrow breathing passages, and trigger symptoms like wheezing and shortness of breath. By binding to IL-5, Nucala prevents eosinophils from maturing and surviving in the blood and lungs, reducing their numbers by up to 84% after consistent dosing.[1][2]
Patients receive it as a 100 mg subcutaneous injection every 4 weeks, often alongside standard asthma controllers like inhaled corticosteroids. This targets the root inflammation rather than just symptoms, cutting severe exacerbations by 47-60% in clinical trials.[1]
Who Qualifies for Nucala Therapy
Nucala is approved for adults and children 6+ with severe asthma where blood eosinophil counts are at least 150 cells/mcL, or those with frequent exacerbations despite high-dose steroids. It's not for acute attacks—use a rescue inhaler for those.[1][3]
How It Differs from Other Asthma Biologics
Unlike broad steroids, Nucala specifically hits IL-5, sparing other immune pathways. Compared to:
- Dupixent (dupilumab): Blocks IL-4/IL-13 for broader allergic asthma.
- Fasenra (benralizumab): Depletes eosinophils directly via cell death.
- Xolair (omalizumab): Targets IgE for allergic asthma.
Nucala suits eosinophil-high cases best, with trials showing it reduces oral steroid use more than placebo.[1][4]
Timeline for Results and Long-Term Use
Exacerbations drop within 4-8 weeks; full benefits like improved lung function emerge by 16-52 weeks. Long-term data from open-label extensions show sustained eosinophil reduction over 5+ years with no new safety signals.[1][2]
Common Side Effects Patients Report
Headaches (19%), injection-site reactions (8%), and back pain affect some users. Rare risks include shingles (get vaccinated) or allergic reactions. Hypersensitivity vasculitis occurred in <1%.[1][3] Monitor eosinophils, as very low counts (<0%) are possible but asymptomatic.
When Does Nucala's Patent Expire
Nucala's key composition-of-matter patent (US 7,582,615) expires in 2025 in the US, opening doors for biosimilars. GSK holds formulation and method patents into the 2030s, with ongoing litigation.[5]
[1]: Nucala Prescribing Information (GSK)
[2]: NEJM: Mepolizumab Efficacy (2014)
[3]: FDA Approval Summary
[4]: Lancet Respiratory: Biologics Comparison
[5]: DrugPatentWatch: Nucala Patents